CYH
BEARISH
$2.72
Live
Community Health Systems, Inc. · NYSE
Target $3.31
(+21.8%)
$2.38
52W Range
$4.47
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 26, 2026
Market cap
$383.29M
P/E
0.79
ROE
N/A
Profit margin
3.8%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
CYH exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio (-0.25), which indicates negative shareholders' equity. While the current P/E ratio appears deceptively low, the surge to a Forward P/E of 20.81 suggests a significant expected collapse in earnings. Revenue is contracting (-6.10% YoY) and the stock is in a persistent technical downtrend, losing 74% of its value over five years. The provided growth-based intrinsic value of $24.08 is fundamentally disconnected from the company's current balance sheet insolvency and should be disregarded.
Key Strengths
Very low Price-to-Sales ratio (0.03)
Current ratio of 1.47 indicates short-term liquidity
Positive operating and profit margins
Analyst target price ($3.31) provides a modest upside from current levels
Occasional massive positive earnings surprises
Key Risks
Negative shareholders' equity (Price/Book: -0.25)
Weak Piotroski F-Score (3/9) indicating deteriorating fundamentals
Negative revenue growth (-6.10% YoY)
Extreme EPS volatility and unpredictable earnings track record
Strong bearish technical trend (0/100)
AI Fair Value Estimate
Based on comprehensive analysis
$3.1
+14.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
30
20
15
10
0
AI Verdict
High Risk / Value Trap
Key drivers: Negative Equity, Piotroski F-Score 3/9, Revenue Contraction, Bearish Price Action
Confidence
90%
Value
30/100
P/E is 0.79 but Forward P/E is 20.81; Graham Number is unavailable due to negative equity.
Positives
- Extremely low P/S ratio
Watchpoints
- Negative P/B ratio
- Forward P/E suggests earnings drop
Future
20/100
Revenue growth is -6.10% YoY.
Positives
- Analyst target price is above current price
Watchpoints
- Negative YoY and Q/Q revenue growth
- Negative EPS growth
Past
15/100
Long-term price performance is severely negative.
Positives
- History of beating estimates in some quarters
Watchpoints
- 5-year price change of -74%
- Consistent downward trend
Health
10/100
Piotroski score indicates weak financial health.
Positives
- Current ratio > 1.0
Watchpoints
- Piotroski F-Score 3/9
- Negative Book Value
Dividend
0/100
Non-dividend paying stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.72
Analyst Target
$3.31
Upside/Downside
+21.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CYH and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CYH
Community Health Systems, Inc.
Primary
|
-74.0% | -54.0% | -5.6% | -33.7% | -7.5% | -13.9% |
|
IRD
Opus Genetics, Inc.
Peer
|
+2.3% | -0.9% | +654.9% | +173.5% | +7.0% | +17.8% |
|
NRC
National Research Corporation
Peer
|
-58.9% | -57.9% | +63.5% | +50.6% | -1.2% | 0.0% |
|
SOPH
SOPHiA GENETICS SA
Peer
|
-68.5% | +3.5% | +86.6% | +22.5% | +7.5% | +12.3% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
CYH
Community Health Systems, Inc.
Primary
5Y
-74.0%
3Y
-54.0%
1Y
-5.6%
6M
-33.7%
1M
-7.5%
1W
-13.9%
IRD
Opus Genetics, Inc.
Peer
5Y
+2.3%
3Y
-0.9%
1Y
+654.9%
6M
+173.5%
1M
+7.0%
1W
+17.8%
NRC
National Research Corporation
Peer
5Y
-58.9%
3Y
-57.9%
1Y
+63.5%
6M
+50.6%
1M
-1.2%
1W
0.0%
SOP
SOPHiA GENETICS SA
Peer
5Y
-68.5%
3Y
+3.5%
1Y
+86.6%
6M
+22.5%
1M
+7.5%
1W
+12.3%
BNR
Burning Rock Biotech Limited
Peer
5Y
-89.9%
3Y
+6.9%
1Y
+414.2%
6M
+415.7%
1M
+65.3%
1W
+9.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
0.79
Forward P/E
20.81
PEG Ratio
2.38
P/B Ratio
-0.25
P/S Ratio
0.03
EV/Revenue
0.89
EV/EBITDA
7.87
Market Cap
$383.29M
Profitability
Profit margins and return metrics
Profit Margin
3.77%
Operating Margin
6.44%
Gross Margin
41.6%
ROE
N/A
ROA
4.68%
Growth
Revenue and earnings growth rates
Revenue Growth
-6.1%
Earnings Growth
N/A
Q/Q Revenue Growth
-6.14%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.47
Good
Quick Ratio
1.19
Good
Cash/Share
$5.26
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$3.0B
Gross Margin
85.1%
Op. Margin
6.4%
Net Margin
-2.0%
Total Assets
$13.2B
Liabilities
$14.1B
Equity
$-1.5B
Debt/Equity
-9.73x
Operating CF
$-0.3B
CapEx
$-0.1B
Free Cash Flow
$-0.4B
FCF Yield
126%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-07-22
$N/A
2026-04-21
$-0.48
-461.4% surprise
2026-02-18
$N/A
+100.0% surprise
2025-10-23
$1.27
+546.7% surprise
Healthcare Sector Comparison
Comparing CYH against 546 companies in the Healthcare sector
(29 bullish, 162 neutral, 355 bearish)
P/E Ratio
0.79
This Stock
vs
77.79
Sector Avg
-99.0%
(Discount)
Profit Margin
3.77%
This Stock
vs
-16.47%
Sector Avg
-122.9%
(Weaker)
Revenue Growth
-6.1%
This Stock
vs
127.18%
Sector Avg
-104.8%
(Slower)
Current Ratio
1.47
This Stock
vs
4.53
Sector Avg
-67.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CYH
Community Health Systems, Inc.
|
BEARISH | $383.29M | 0.79 | -% | 3.8% | $2.72 | |
|
IRD
Opus Genetics, Inc.
|
BEARISH | $381.36M | - | -242.4% | -% | $5.36 | Compare |
|
NRC
National Research Corporation
|
BEARISH | $387.6M | 34.08 | 51.2% | 8.4% | $17.04 | Compare |
|
SOPH
SOPHiA GENETICS SA
|
BEARISH | $378.41M | - | -110.0% | -102.2% | $5.28 | Compare |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | Compare |
CYH
Community Health...
BEARISH
Mkt Cap
$383M
P/E
0.8
ROE
-%
Price
$2.72
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | KRISHNAN K RANGA | Director | Stock Award | 46,950 | - |
| 2026-03-02 | SMITH WAYNE T | Director | Gift | 19,400 | - |
| 2026-02-27 | HIRSCH ELIZABETH T | Director | Stock Award | 50,595 | - |
| 2026-02-27 | HAMMONS KEVIN J | Chief Executive Officer | Stock Award | 200,000 | - |
| 2026-02-27 | HAMMONS KEVIN J | Chief Executive Officer | Stock Award | 156,240 | - |
| 2026-02-27 | WILLIAMS HUBERT JAMES | Director | Stock Award | 50,595 | - |
| 2026-02-27 | JOHNSON JASON K | Chief Financial Officer | Stock Award | 90,000 | - |
| 2026-02-27 | JOHNSON JASON K | Chief Financial Officer | Stock Award | 30,000 | - |
| 2026-02-27 | BROOKS SUSAN W. | Director | Stock Award | 50,595 | - |
| 2026-02-27 | STOCKTON KEVIN A | Officer | Stock Award | 30,000 | - |
| 2026-02-27 | STOCKTON KEVIN A | Officer | Stock Award | 50,000 | - |
| 2026-02-27 | ELY JAMES S III | Director | Stock Award | 50,595 | - |
| 2026-02-27 | FRY JOHN ANDERSON | Director | Stock Award | 50,595 | - |
| 2026-02-27 | DINKINS MICHAEL | Director | Stock Award | 30,662 | - |
| 2026-02-27 | PITT JUSTIN D. | President | Stock Award | 40,000 | - |
KRISHNAN K RANGA
Director
2026-04-22
46,950 shares
SMITH WAYNE T
Director
2026-03-02
19,400 shares
HIRSCH ELIZABETH T
Director
2026-02-27
50,595 shares
HAMMONS KEVIN J
Chief Executive Officer
2026-02-27
200,000 shares
HAMMONS KEVIN J
Chief Executive Officer
2026-02-27
156,240 shares
WILLIAMS HUBERT JAMES
Director
2026-02-27
50,595 shares
JOHNSON JASON K
Chief Financial Officer
2026-02-27
90,000 shares
JOHNSON JASON K
Chief Financial Officer
2026-02-27
30,000 shares
BROOKS SUSAN W.
Director
2026-02-27
50,595 shares
STOCKTON KEVIN A
Officer
2026-02-27
30,000 shares
STOCKTON KEVIN A
Officer
2026-02-27
50,000 shares
ELY JAMES S III
Director
2026-02-27
50,595 shares
FRY JOHN ANDERSON
Director
2026-02-27
50,595 shares
DINKINS MICHAEL
Director
2026-02-27
30,662 shares
PITT JUSTIN D.
President
2026-02-27
40,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
7 analysts
Truist Securities
2026-04-23
Hold
Hold
Barclays
2026-04-23
Equal-Weight
Equal-Weight
Truist Securities
2026-04-13
Hold
Hold
UBS
2026-02-20
Neutral
Neutral
Wells Fargo
2026-01-07
Underweight
Underweight
Past News Coverage
Recent headlines mentioning CYH from our newsroom.
Newest → oldest
No matching news yet.